Investigating the Relationship between Serum Level of s-Met (Soluble Hepatic Growth Factor Receptor) and Preeclampsia in the First and Second Trimesters of Pregnancy.

Farshad Naghshvar,Parand Gheshlaghi,Zhila Torabizadeh,Hooman Mirbaha,Narges Moslemi Zadeh

doi:10.1155/2013/925062

Farshad Naghshvar, Parand Gheshlaghi + Show 3 more

Open Access

https://doi.org/10.1155/2013/925062

Copy DOI

Abstract

Introduction. Preeclampsia (PE) is an important cause of mortality and morbidity for mothers, fetuses, and the newborns. Placenta plays a pivotal role in pathogenesis of PE. Hepatic growth factor (HGF) is a cytokine expressed by the mesenchymal stalk of placental villi during pregnancy and assumes a paracrine role in trophoblasts which express its receptor (c-MET). In the present study, we investigate the diagnostic value of s-Met (the soluble form of the receptor) in the first and second trimesters of pregnancy for early diagnosis of preeclampsia. Method and Materials. This is a case-control study conducted on 95 pregnant women. The serum level of s-Met was measured in the first and second trimesters, and the participants were followed until delivery. 44 individuals with preeclampsia (the case group) and 51 individuals without preeclampsia (the control group) were evaluated. Results. Serum level of s-Met in preeclamptic participants was lower than that of the control group in both the first and the second trimesters (P < 0.0001). In addition, serum levels of s-Met were significantly lower during the first and second trimesters in patients with early, severe preeclampsia compared to those with late, mild preeclampsia (P < 0.0001). The sensitivity and specificity of s-Met in the first and second trimesters were, respectively, (83%, 94%) and (77%, 94%) for early preeclampsia and (88%, 92%) and (86%, 98%) for severe preeclampsia. Conclusion. Considering our findings, serum level of s-Met may be used as a predictive factor for early detection of preeclampsia. Further research is required to corroborate the functional and therapeutic value of s-Met in preeclampsia.

Highlights

Preeclampsia (PE) is an important cause of mortality and morbidity for mothers, fetuses, and the newborns
Preeclampsia (PE) is a condition characterized by hypertension and proteinuria in pregnant women, where hypertension is defined as blood pressure equal to or exceeding 140/ 90 mmHg after the 20th week of gestation, and proteinuria is defined as either urinary excretion of more than 300 mg protein in 24 hours or presence of 3 mg/dL (≥1+ dipstick test) protein in two random urine samples [1]
Considering the role of s-Met in regulation of angiogenesis and other processes regulated by the Hepatic growth factor (HGF), it has been hypothesized that abnormal serum levels of s-Met may be beneficial in early diagnosis of preeclampsia before the clinical syndrome [4]

Summary

Introduction

Preeclampsia (PE) is an important cause of mortality and morbidity for mothers, fetuses, and the newborns. Hepatic growth factor (HGF) is a cytokine expressed by the mesenchymal stalk of placental villi during pregnancy and assumes a paracrine role in trophoblasts which express its receptor (c-MET). We investigate the diagnostic value of s-Met (the soluble form of the receptor) in the first and second trimesters of pregnancy for early diagnosis of preeclampsia. Certain biochemical markers have been proposed for early diagnosis of preeclampsia, including placental protein 13 (pp-13) and a protein produced by the growing trophoblast (PAPPA) [3] Another marker of interest is the hepatic growth factor (HGF) which regulates cell growth, differentiation, and morphology [1]. A study by Zeng et al [4] reported that lowered plasma level of s-Met may be a potential biomarker for predicting severe preeclampsia early in the second trimester. Shin et al concluded that elevated plasma levels of s-Met in the second trimester may be helpful for early detection of preeclampsia [5]

Methods

Results

Conclusion